

November 25, 2014



Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide

Intellectual property covers compounds, methods, uses and multiple geographies with 10 patents recently granted and 13 allowed

LEXINGTON, Mass.-- **Xenetic Biosciences, Inc. (OTCBB:XBIO)**, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today provided an update on recent patent grants and allowances worldwide.

Since May 2014, the Company has been issued 10 patents, including six in the U.S., two in Japan and one each in New Zealand and India. In addition, 13 patents have been allowed, including seven in the U.S., two each in Japan and South Korea, and one each in Russia and Canada. Xenetic Biosciences now has over 140 issued patents worldwide and approximately 80 pending patents.

Select key patents issued recently by the U.S. Patent and Trademark Office include Patent No. 8,796,207, *Derivatisation of erythropoietin (EPO)*, which relates to novel polysaccharide derivatives of EPO and methods for producing such derivatives. The derivatives are useful for improving the stability, pharmacokinetics and pharmacodynamics of EPO. This same patent was also issued in Japan during the third quarter.

U.S. Patent No. 8,735,557, *Activated sialic acid derivatives for protein derivatisation and conjugation*, was also recently granted and relates to polysialic acid and derivatives of polysialic acids which have terminal sialic acid units. This patent covers the targeted conjugation of polysialic acid and its derivatives to therapeutics such as peptides, proteins, drugs, drug delivery systems, etc.

Also issued during the third quarter was U.S. Patent No. 8,828,405, *Method to Enhance an Immune Response of Nucleic Acid Vaccination*. This patent relates to a composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein. The composition provides an improved immune response compared with mixtures of liposomes, some of which are associated with the nucleic acid and some of which are associated with the assistor protein.

"Xenetic Biosciences has a substantial patent portfolio to rival any biotech company many times our size. This work results directly from our previous strategy focused on research. Now that we have transformed into a clinical development company, we are well positioned for potentially monetizing our extensive intellectual property portfolio. We expect to add 13 additional patents over the next three months," said M. Scott Maguire, chief executive officer of Xenetic Biosciences. "We are particularly pleased with our intellectual property position in

Japan as those patent grants are typically difficult to secure. Our IP relates not only to our 'bio-better' EPO, our lead candidate, but also to improving availability of a number of protein-based drugs. We recently received an allowance for a U.S. patent relating to novel polysaccharide derivatives of granulocyte colony-stimulating factor (GCSF) and methods for producing such derivatives. The derivatives are useful for improving the stability, pharmacokinetics and pharmacodynamics of GCSF. Our expectations are that we will have strong intellectual property protection for many years after our lead compounds have progressed through the U.S. regulatory process," Mr. Maguire added.

About Xenetic Biosciences

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next-generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs, and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory acute myeloid leukemia (AML). Xenetic is developing a novel series of polysialylated blood coagulation factors through its license agreement with Baxter International Inc. Xenetic is also developing a broad pipeline of clinical candidates for next-generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit www.xeneticbio.com.

Xenetic Biosciences Inc.
M. Scott Maguire, Chief Executive Officer
781-778-7720

j.mccusker@xeneticbio.com

or

U.S. Contact:

LHA

Kim Sutton Golodetz
212-838-3777

kgolodetz@lhai.com

or

UK/European Contact:

Walbrook PR

Mike Wort

+44 (0)20 7933 8780

mike.wort@walbrookpr.com

Source: Xenetic Biosciences, Inc.